Dupilumab: A novel treatment for asthma

Journal of Asthma and Allergy

Volumn 7, Issue , 2014, Pages 123-130

  Vatrella, Alessandro ^a   Fabozzi, Immacolata ^a   Calabrese, Cecilia ^b   Maselli, Rosario ^c   Pelaia, Girolamo ^c  

^a UNIVERSITY OF SALERNO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Dupilumab; Interleukin 13; Interleukin 4; Th2 high asthma

Indexed keywords

ALTRAKINCEPT; ANRUKINZUMAB; CD4 ANTIGEN; DUPILUMAB; EOTAXIN 3; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR BETA; INTERLEUKIN 5; JANUS KINASE 1; JANUS KINASE 2; LEBRIKIZUMAB; PASCOLIZUMAB; PITRAKINRA; STAT6 PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ASTHMA; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH2 CELL;

EID: 84911453681     PISSN: 11786965     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S52387     Document Type: Review

References (50)

1. Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther. 2013;26(6):710–715.
2. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39.
3. Holt PG, Sly PD. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest. 2011;139(5):1165–1171.
4. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009;15(4):410–416.
5. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major sub-phenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395.
6. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med. 2006;203(2):269–273.
7. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol. 2003;111(3): 450–463.
8. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117–129.
9. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556.
10. Kaiko GE, Foster PS. New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2011;11(1):39–45.
11. Scanion ST, McKenzie ANJ. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol. 2012;24(6):707–712.
12. Halim TY, McKenzie AN. New kids on the block – group 2 innate lymphoid cells and type 2 inflammation in the lung. Chest. 2013;144(5):1681–1686.
13. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin 4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66–70.
14. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–420.
15. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19(115):46–54.
16. Andrews R, Rosa L, Daines M, Khurana HG. Reconstitution of a functional human type II IL-4/IL-13 in mouse B cells: demonstration of species specificity. J Immunol. 2001;166(3):1716–1722.
17. Chiba Y, Goto K, Misawa M. Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells. Pharmacol Rep. 2012;64(2):454–458.
18. Zheng T, Liu W, Oh SY, et al. IL-13 receptor α2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol. 2008;180(1):522–529.
19. Maes T, Joos GF, Brusselle GG. Targeting IL-4 in asthma: lost in translation? Am J Respir Cell Mol Biol. 2012;47(3):261–270.
20. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685–691.
21. Corren J. Anti-interleukin-13 antibody therapy for asthma: one step closer. Eur Respir J. 2013;41(2):255–256.
22. Prieto J, Lensmar C, Roquet AI, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94(8):806–814.
23. Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL-13 in a Dutch population with asthma. Am J Hum Genet. 2002;70(1):230–236.
24. Li X, Howard TD, Zheng SL, et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol. 2010;125(2):328–335.
25. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998; 282(5397):2261–2263.
26. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258–2261.
27. Munitz A, Brandt EB, Mingler M, et al. Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A. 2008;105(20):7240–7245.
28. Kotsimbos TC, Ernst P, Hamid QA, et al. Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians. 1996;108(5):368–373.
29. Coyle AJ, Le Gros G, Bertrand C, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995;13(1):54–59.
30. Swart DA, Anders-Bartholo PM, Tocker JE. Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice. J Allergy Clin Immunol. 2008;121(2):S267.
31. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11(12):958–972.
32. Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am. 2004;24(4):599–614.
33. Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol. 2009;49(9):1025–1036.
34. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J Allergy Clini Immunol. 2011;128(3):495–505.
35. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596): 1422–1431.
36. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol. 2012;130(2):516–522.
37. Yang G, Volk A, Petley T, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28(6):224–232.
38. Blanchard C, Mishra A, Saito-Hakei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096–1103.
39. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338.
40. Gauvreau GM, Boulet LP, Cockroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183(8):1007–1014.
41. Thomson NC, Patel M, Smith AD. Lebrikizumab in the personalized management of asthma. Biologics. 2012;6:329–335.
42. Yuyama N, Davies DE, Akaiwa M, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19(6):287–296.
43. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104.
44. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–654.
45. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
46. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132(3):567–574.
47. De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAB in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133(4):989–996.
48. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
49. Wechsler ME. Inhibiting IL-4 and IL-13 in difficult-to-control asthma. N Engl J Med. 2013;368(26):2511–2513.
50. Gallelli L, Busceti MT, Vatrella A, Maselli R, Pelaia G. Update on anti-cytokine treatment for asthma. Biomed Res Int. 2013;2013:104315.